The acetylcholinesterase inhibitors (AChEIs) donepezil, rivastigmine and galantamine and the N-methyl-d-aspartate (NMDA) receptor antagonist memantine are recommended in several countries for the symptomatic management of dementia due to AD and Lewy body disease (DLB and PD with related dementia; PDD). Here, ACHE is linked to Lewy body dementia.